What Rosemont Pharmaceuticals does

Rosemont Pharmaceuticals is a UK-based specialty pharmaceutical manufacturer specializing in oral liquid medicines for patients with dysphagia (swallowing difficulties). Founded approximately 60 years ago and headquartered in Leeds (Rosemont House, Yorkdale Industrial Park, Braithwaite Street, LS11 9XE), the company manufactures and supplies branded and generic prescription oral liquid medications serving stroke patients, dementia patients, head and neck cancer patients, people with intellectual disabilities, older patients, and children who cannot swallow tablets or capsules. The company is privately held and PE-backed, registered as Rosemont Pharmaceuticals Limited in England and Wales (company number 00924648), with additional operations in South Carolina (USA) and Athens (Greece). It employs 290 staff as of the 2024-25 reporting period and has been recognized as one of the fastest growing PE-backed mid-market businesses over the past three years.

The company's core technology is oral liquid medicine formulation and manufacturing, delivered through a state-of-the-art UK manufacturing facility and R&D expertise located in the UK and Greece. The product portfolio includes licensed and unlicensed 'Specials' medicines, with expanded capabilities in unit dose and sachet formats acquired through Lucis Pharma Ltd (June 2023) and direct US supply capabilities acquired through Sabal Therapeutics (July 2024). A notable product launch is ATMEKSI (methocarbamol) Oral Suspension, scheduled for nationwide US launch in March 2026, providing a muscle relaxant option for patients aged 16 and older with swallowing difficulties. The company addresses a documented clinical need, citing that 37% of general practice patients experience difficulty swallowing tablets or capsules.

Rosemont operates a B2B prescription pharmaceutical revenue model targeting healthcare professionals including doctors, pharmacists, and speech and language therapists, supplemented by direct-to-consumer patient education resources. Products are distributed through healthcare professional prescriptions, online pharmacy channels (rosemontpharma.com) for registered UK purchasers, third-party international distribution partners across 40+ markets, and direct US supply established post-Sabal. Pricing is determined through healthcare system channels and insurance coverage rather than public disclosure. The company is led by CEO Alok Sonig (effective January 1, 2026) with Chairman Sharon Curran on the board, and recently won a major UK pharmaceutical industry award in 2025.

Name

Rosemont Pharmaceuticals

Legal name

Rosemont Pharmaceuticals Limited

Website

https://rosemontpharma.com

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

101–250 employees

Short description

Rosemont Pharmaceuticals is a UK-based PE-backed specialty pharmaceutical manufacturer producing oral liquid medicines for patients with dysphagia. Founded nearly 60 years ago, the company supplies branded and generic prescription products across 40+ international markets with newly established direct US operations.

Ownership category

akta.pro rank

Product category

Oral Liquid Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Oral liquid medicines
• Specialty pharmaceuticals
• Generic drug manufacturing
• Dysphagia medications
• Liquid formulations

Headquarters

HQ city

Leeds

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Sale of branded and generic prescription oral liquid medicines to healthcare providers and patients globally. Revenue generated through direct supply and distribution partnerships across international markets.
2. Product Licensing and Supply: Direct supply capabilities in US market following Sabal Therapeutics acquisition, expanding portfolio of liquid medicines for patients with swallowing difficulties

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Rosemont Pharmaceuticals manufactures and supplies oral liquid medicines designed for patients who have difficulty swallowing solid dosage forms, including those with dysphagia. The company produces both branded and generic liquid pharmaceutical formulations distributed to healthcare providers, wholesalers, and distributors across more than 40 international markets. Its portfolio spans muscle relaxants and other therapeutic categories reformulated as oral suspensions and solutions.

Product overview

Rosemont Pharmaceuticals is a specialty pharmaceutical company and a global leader in oral liquid medicines with nearly 60 years of experience. The company operates a platform-based model focused on developing, manufacturing, and supplying novel, prescription oral liquid medicines primarily for patients with swallowing difficulties (dysphagia). The portfolio includes branded and generic liquid medications, supported by acquired capabilities from Sabal Therapeutics (US market expansion) and Lucis Pharma Ltd (UK-based liquid medicine specialist with unit dose/sachet products). The company maintains state-of-the-art manufacturing in the UK with R&D expertise in the UK and Greece, supplying over 40 international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• ATMEKSI (methocarbamol) Oral Suspension An oral liquid suspension formulation of methocarbamol (a muscle relaxant) for patients who cannot swallow solid dosage forms, including those with dysphagia. Launched in the US market and sold to healthcare providers via Rosemont's US distribution channels.
• Branded Oral Liquid Medicines Proprietary branded oral liquid pharmaceutical formulations manufactured by Rosemont for patients with dysphagia and other swallowing difficulties, distributed through wholesalers, hospitals, and pharmacies across 40+ international markets.
• Generic Oral Liquid Medicines Generic oral liquid pharmaceutical formulations offered as cost-effective alternatives to branded products, primarily for patients with swallowing difficulties across multiple therapeutic categories.

Quantifiable outcome

• 37% of general practice patients experience difficulty swallowing tablets or capsules
• +1 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Sabal TherapeuticscoreStrategic or Co-development Partner · 9 July 2024Acquired US-based Sabal Therapeutics and affiliates operating in Georgia, USA to enhance direct supply capabilities in US market. Expands portfolio of liquid medicines for patients with swallowing difficulties and supports pipeline of new products. Enables direct supply of branded and generic medicines in US market.
• Lucis Pharma LtdcoreStrategic or Co-development Partner · 16 June 2023Acquired UK-based Lucis Pharma Ltd to expand product portfolio and pipeline of innovative medicines. Provides access to new therapeutic areas and pipeline products including unit dose and sachet markets. Enhances global reach and creates growth opportunities for liquid medications targeting dysphagic patients.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Colonis Pharma: UK-based specialty pharmaceutical company focused on liquid medicines and 'Specials' manufacturing for patients with swallowing difficulties. Directly comparable to Rosemont in target customers (dysphagia patients, NHS prescribers), product format (oral liquids), and regulatory positioning.
• Thame Laboratories: UK-based pharmaceutical company specializing in liquid and specialty formulations, including products for patients with dysphagia. Overlaps with Rosemont in finished dosage form (FDF) liquid manufacturing, prescription model, and UK healthcare professional channel.
• Essential Pharma: Specialty pharmaceutical company focused on niche, established medicines often with limited commercial alternatives. Comparable to Rosemont in niche specialty positioning, focus on underserved patient populations, and specialty FDF manufacturing.

Broad incumbents

• Hikma Pharmaceuticals: Global generic pharmaceutical manufacturer with significant oral liquid and specialty product portfolio across the US, MENA, and Europe. Comparable to Rosemont in generic and specialty FDF manufacturing and global distribution, though at much larger scale and broader therapeutic breadth.
• Aspen Pharmacare: Global specialty and generic pharmaceutical company with a strong portfolio of complex finished dosage forms including oral liquids. Comparable to Rosemont in specialty FDF manufacturing, focus on niche therapeutic areas, and multi-region distribution.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with a broad portfolio of finished dosage forms including oral liquids. Comparable to Rosemont in generic FDF manufacturing at scale, though Teva competes across a vastly wider therapeutic footprint.
• Sandoz (Novartis): Global leader in generic pharmaceuticals with oral solid, injectable, and liquid dosage forms. Comparable to Rosemont in generic finished dosage form manufacturing and global distribution, but operates at much larger scale and across a broader portfolio.
• Perrigo Company: Global consumer self-care and generic pharmaceutical company with significant oral liquid product lines (including store-brand OTC liquids). Comparable to Rosemont in liquid oral dosage form manufacturing and pharmacy/retail distribution channels.
• GSK: Major UK-headquartered pharmaceutical company with broad prescription and specialty medicine portfolios, including liquid formulations. Comparable to Rosemont as a UK pharma peer operating in prescription medicines with global reach, though at vastly larger scale.

Emerging players

• Alvotech: Specialty biopharmaceutical company focused on biosimilars and complex finished dosage form development. Comparable to Rosemont in the broader theme of specialty, complex FDF development and global commercialization, though in biologics rather than small-molecule oral liquids.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rosemont-pharmaceuticals-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rosemont Pharmaceuticals